RATING

RECOMMENDATION

Strong Sell

  • ROFR Required
  • Available in Depository:

  • NSDL

  • CDSL

  • Available for Investment:

  • Primary

  • Secondary

RATING

RECOMMENDATION

Strong Sell

Business Type

Traditional Business

RATING

RECOMMENDATION

Strong Sell

Business Type

Traditional Business

Arch Pharmalabs Profit and Loss

  • Higher than industry Revenue growth

    Total Revenue has increased by 41.9% over the last 3 years v/s the 5-year industry average of 7.7%

  • Lower than Industry Net Income

    Over the last 3 years, net income has fallen at a yearly rate of -32.37% v/s 5 years the industry average of 3.81% 

Financial Year

Total Revenue
COGS
Gross Profit
Raw Materials
Power & Fuel Cost
Employee Cost
Sales & Administrative Expenses
Operating & Other Expenses
EBITDA
Depreciation/ Amortization
PBIT
Interest & Income
Interest & Expense
Other Items
PBT
Taxes & Other Items
Net Income
Diluted EPS
Basic EPS
DPS
Payout Ratio
FY 2018

247.44

184.41

63.03

63.24

-

48.68

-

213.88

-262.77

39.1

-301.87

-

82.52

-

-384.39

-323.25

-61.14

-8.92

-8.92

-

-

FY 2019

514.78

416.86

97.92

-67.5

-

63.85

-

49.31

52.26

32.54

19.72

-

162.86

-

-143.14

-11.8

-131.33

-8.64

-8.64

-

-

FY 2020

651.5

563.08

88.42

-86.06

-

61.63

-

55.21

57.64

30.3

27.34

-

210.83

-

-183.48

-23.98

-159.5

-10.5

-10.5

-

-

FY 2021

798.58

444.47

354.11

21.14

-

74.12

-

891.67

-632.82

27.8

-660.62

-

230.84

-

-891.45

-2,760.89

1,869.44

123.05

123.05

-

-

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ Cr

* denotes current year's data

  • Arch Pharmalabs Annual Reports

2019

Annual Reports

2020

Annual Report

2021

Annual Report